Novartis, Microsoft ink 5-year AI alliance
Novartis announced a five-year partnership with Microsoft in a bet that the tech company can help it make better sense of the data they generate from lab experiments, clinical trials, and manufacturing plants.
They will develop applications for Microsoft’s AI capabilities throughout Novartis’ drug development, focusing first on personalizing treatment for age-related macular degeneration and on improving manufacturing of CAR-T cancer therapies.
Additionally, through a new AI innovation lab, the companies hope to make AI-powered applications accessible and usable across Novartis’ organization.
